- Conditions
- Cystic Fibrosis
- Interventions
- Ataluren (PTC124®), Placebo
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Long Beach, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 21,535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- MM-141
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 3
- States / cities
- Marietta, Georgia • Boston, Massachusetts • Detroit, Michigan
- Conditions
- Pancreatic Ductal Carcinoma
- Interventions
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel, Gemcitabine
- Other · Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 52 more
- Conditions
- Multiple Myeloma
- Interventions
- zevor-cel
- Biological
- Lead sponsor
- CARsgen Therapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2034
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
- Conditions
- Acute Myeloid Leukemia, Acute Myelogenous Leukemia
- Interventions
- Standard dose cytarabine for induction, SGN-CD33A, Daunorubicin, High dose cytarabine for consolidation
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Denver, Colorado + 10 more
- Conditions
- Angelman Syndrome, Nervous System Diseases
- Interventions
- Betaine, Creatine, Metafolin, Vitamin B12
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 4
- States / cities
- San Diego, California • Boston, Massachusetts • Greenwood, South Carolina + 1 more
- Conditions
- Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
- Interventions
- Pregabalin, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more
- Conditions
- Leukemia
- Interventions
- hydroxyurea, Homoharringtonine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
- Conditions
- Asthma
- Interventions
- CareTRx
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Fludarabine, Obinutuzumab, Bendamustine, Cyclophosphamide
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 18
- States / cities
- Huntsville, Alabama • Duarte, California • La Jolla, California + 15 more
- Conditions
- Osteoarthritis,Knee
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 45 Years to 79 Years
- Enrollment
- 4,185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2020
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts
- Conditions
- Advanced Microsatellite Stable Colorectal Cancer
- Interventions
- Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- North Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 2 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- BIBW 2992
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- RO6885247, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Up to 55 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Stanford, California • Orlando, Florida • Chicago, Illinois + 3 more
- Conditions
- Nonhemorrhagic Ischemic Stroke, Motor Function
- Interventions
- Observational study
- Other
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 22
- States / cities
- Newport Beach, California • Englewood, Colorado • Lawrenceville, Georgia + 18 more
- Conditions
- Abnormality in Fetal Heart Rate or Rhythm
- Interventions
- Not listed
- Lead sponsor
- Mindchild Medical Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Akron, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
- Conditions
- Brain Injuries, Traumatic
- Interventions
- Head and Intraocular Trauma Tool
- Device
- Lead sponsor
- Rebiscan, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anesthesia, Dental
- Interventions
- Phentolamine Mesylate (NV-101)
- Drug
- Lead sponsor
- Novalar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoid Syndrome
- Interventions
- Panitumumab
- Drug
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Burlington, Massachusetts
- Conditions
- Migraine With Aura, Migraine Without Aura
- Interventions
- Dronabinol MDI
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 29
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
- Conditions
- Communication
- Interventions
- Family-centered nighttime communication bundle
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 1,334 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Interventions
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids
- Drug · Procedure
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Ovarian Clear Cell Carcinoma, Gynecologic Cancer
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Elizabeth K. Lee MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota